Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Jiancheng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8136-2008; OpenAlex author ID A5100599547. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers

Papers 9

  1. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  2. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2411868/v1↗
  3. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-022-01272-w↗
  4. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1. Co-author DOI 10.1186/s13045-022-01348-7↗
  5. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2065916/v1↗
  6. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  7. Original study: The rescue staging for pancreatic ductal adenocarcinoma with inadequate examined lymph nodes. Co-author DOI 10.1016/j.pan.2021.02.010↗
  8. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3425↗
  9. Small nuclear ribonucleoprotein associated polypeptide N accelerates cell proliferation in pancreatic adenocarcinoma. Last author DOI 10.3892/mmr.2015.4208↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chenghong Peng · 7 shared papers, 2020–2023 · strength 0.88
  2. Baiyong Shen · 4 shared papers, 2020–2022 · strength 0.45
  3. Chenlei Wen · 4 shared papers, 2020–2023 · strength 0.45
  4. Dongfeng Cheng · 4 shared papers, 2020–2023 · strength 0.44
  5. Xiaxing Deng · 4 shared papers, 2020–2023 · strength 0.44
  6. Jiewei Lin · 3 shared papers, 2022–2023 · strength 0.44
  7. Yizhi Cao · 3 shared papers, 2022–2023 · strength 0.42
  8. Siyi Zou · 3 shared papers, 2021–2023 · strength 0.36
  9. Jiabin Jin · 3 shared papers, 2020–2023 · strength 0.31
  10. Hao Chen · 3 shared papers, 2020–2022 · strength 0.31
  11. Baiyong Shen · 2 shared papers, 2022–2023 · strength 0.28
  12. Hao Chen · 2 shared papers, 2021–2023 · strength 0.28
  13. Zengyu Feng · 2 shared papers, 2022–2023 · strength 0.28
  14. Lijie Han · 2 shared papers, 2022–2023 · strength 0.28
  15. Kexian Li · 2 shared papers, 2022–2023 · strength 0.28
  16. Yongsheng Jiang · 2 shared papers, 2022–2023 · strength 0.28
  17. Kai Qin · 2 shared papers, 2022–2023 · strength 0.28
  18. Xiongxiong Lu · 2 shared papers, 2021–2023 · strength 0.22
  19. Yangbing Jin · 2 shared papers, 2021–2023 · strength 0.22
  20. Henghui Zhang · 2 shared papers, 2021–2023 · strength 0.22
  21. Qian Zhan · 2 shared papers, 2020–2021 · strength 0.18
  22. Jun Zhang · 2 shared papers, 2020–2021 · strength 0.18
  23. Shuyu Zhai · 1 shared paper, 2022 · strength 0.16
  24. Da Fu · 1 shared paper, 2022 · strength 0.16
  25. Xiaxing Deng · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.